Olumiant is also approved to treat rheumatoid arthritis and some hospitalised patients with COVID-19, and made more than $1.1 billion from its approved indications last year.

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...